Polomar Health Services, Inc. filed a Form 10-Q with the SEC on November 16, 2026, reporting unaudited financial results for the quarterly period ended September 30, 2026.

Key Highlights

  • Revenue surge: The company reported nine-month revenue of $3,739,944 for the period ended September 30, 2026, compared to $16,174 for the same period in 2025, according to the filing.
  • Net loss: Net loss for the nine months ended September 30, 2026 was $829,002, versus a net loss of $1,712,193 for the same period in 2025.
  • Accumulated deficit: The accumulated deficit reached $14,565,652 as of September 30, 2026, up from $13,612,268 as of December 31, 2025.
  • Stockholders' deficit: Total stockholders' deficit was $(2,835,191) as of September 30, 2026, compared to $(1,972,329) as of December 31, 2025.
  • Shares outstanding: The company reported 28,380,868 common shares outstanding as of November 13, 2026.
  • Restatement noted: The balance as of June 30, 2026 is labeled "As Restated" in the condensed consolidated statements of stockholders' deficit, with a reference to Note 3.
  • Series A preferred stock: 167 shares of Series A convertible preferred stock were issued and outstanding as of September 30, 2026, with a liquidation value of $5,000 per share and a carrying value of $835,000.

Polomar Health Services Financial Position for the Nine Months Ended September 30, 2026

According to the filing, Polomar Health Services, Inc. reported total revenue of $3,739,944 for the nine months ended September 30, 2026, a sharp increase from $16,174 for the comparable prior-year period. For the third quarter alone, the company disclosed revenue of $1,133,775 versus $6,163 in the three months ended September 30, 2025. Cost of goods sold for the nine-month period was $2,041,912, producing a gross profit of $1,698,032.

Despite the revenue growth, the company reported a net loss of $829,002 for the nine months ended September 30, 2026, compared to a net loss of $1,712,193 for the same period in 2025. Total operating expenses for the nine-month period were $2,415,370, including general and administrative expenses of $744,433 and sales and marketing expenses of $1,670,937, according to the filing. Interest expense of $111,664 was also recorded for the nine-month period. Net loss attributable to common stockholders for the nine months was $(953,384), after accounting for $124,382 in dividends on Series A convertible preferred stock.

The company's balance sheet as of September 30, 2026 showed total assets of $886,874 and total liabilities of $2,887,065, resulting in a total stockholders' deficit of $(2,835,191). Cash on hand was reported at $254,779. The filing also notes that the June 30, 2026 balance in the stockholders' deficit statement is labeled "As Restated," with the company directing readers to Note 3 of the financial statements. The securities registered under Section 12(b) of the Act are listed as "N/A" in the filing's cover page, with no exchange or trading symbol indicated.

What Was Disclosed

Polomar Health Services filed a quarterly report covering the period ended September 30, 2026, disclosing revenue of $3,739,944 for nine months, a net loss of $829,002, an accumulated deficit of $14,565,652, and a restatement of its June 30, 2026 stockholders' deficit balance.